EODData

FRA, 1ZL: Zai Lab Limited

03 Sep 2025
LAST:

28.00

CHANGE:
 0.20
OPEN:
28.00
HIGH:
28.00
ASK:
0.00
VOLUME:
20
CHG(%):
0.71
PREV:
28.20
LOW:
28.00
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Sep 2528.0028.0028.0028.0020
02 Sep 2528.0028.2028.0028.2020
01 Sep 2527.8027.8027.8027.8020
29 Aug 2528.0028.0027.6027.6020
28 Aug 2526.8026.8026.8026.8020
27 Aug 2528.6028.6028.0028.0020
26 Aug 2528.8028.8028.8028.80200
25 Aug 2529.0029.0029.0029.00200
22 Aug 2529.0029.0029.0029.00200
21 Aug 2528.4028.4028.4028.40200

COMPANY PROFILE

Name:Zai Lab Limited
About:Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Sector:Healthcare
Industry:Biotechnology
Address:Building B, Pudong, China, 201203
Website:https://www.zailaboratory.com
ISIN:US98887Q1040
LEI:549300P2UYQ9U5LY1T58

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

TECHNICAL INDICATORS

MA5:27.68
MA10:28.16
MA20:29.05
MA50:30.18
MA100:29.42
MA200:28.73
STO9:54.55
STO14:30.00
RSI14:35.14
WPR14:-70.00
MTM14:-2.40
ROC14:-0.08
ATR:0.61
Week High:28.60
Week Low:26.80
Month High:34.01
Month Low:26.80
Year High:38.06
Year Low:16.88
Volatility:42.34